SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently facing intense volatility as market participants weigh a controversial short report alleging that Anthropic is gaining market share against the stock's role as a mission-critical AI platform for government and enterprise clients. Community sentiment is deeply divided, with many investors dismissing the negative commentary as market manipulation while others express concern over the company's valuation and intensifying competition in the AI sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure as market participants react to a combination of bearish analyst earnings revisions, concerns over delivery figures, and skepticism regarding the long-term feasibility of its robotaxi and robotics initiatives. The community remains deeply divided, with some investors betting on a technical breakdown and structural overvaluation, while others view the volatility as a potential buying opportunity driven by institutional positioning and future product potential.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is experiencing intense selling pressure and volatility as investors weigh lingering geopolitical uncertainty against broader AI sector concerns, with community sentiment deeply polarized between those identifying a potential long-term value opportunity and frustrated traders struggling with the stock's persistent underperformance relative to its peers. Market participants remain fixated on upcoming earnings as the primary catalyst to either validate the company's AI-driven growth narrative or deepen existing bearish skepticism.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to the company joining Elon Musk's ambitious 'Terafab' initiative, which aims to produce high-performance chips for Tesla, SpaceX, and xAI. The community is actively debating the stock's long-term potential as a 'sovereign foundry' play, with many traders focused on a potential breakout toward the $60 level while closely monitoring broader geopolitical volatility.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as investors rotate into beaten-down enterprise software names following recent institutional accumulation and optimistic commentary from leadership regarding the platform's AI-driven workflow capabilities. The community is actively debating whether this movement marks a sustainable reversal or a temporary technical bounce, with significant focus on the stock's ability to maintain momentum above key support levels.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is facing significant volatility as market participants weigh a volatile Middle East ceasefire against aggressive algorithmic support that continues to prop up prices. While sentiment remains divided over the stability of the deal and regional geopolitical tensions, the community is heavily focused on conflicting reports regarding the status of the Strait of Hormuz and potential future market manipulation.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors weigh its pivot toward agentic AI against intense competition and bearish market sentiment, despite the company's strong balance sheet and profitability. Community discussions are highly polarized, with some investors accumulating shares as a long-term value play, while others express frustration over the stock's persistent price stagnation and potential displacement by evolving AI technologies.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as traders grapple with extreme volatility and conflicting geopolitical signals, particularly following news regarding the Strait of Hormuz and skepticism toward recent peace talks. The community is sharply divided, with some actively trading quick intraday swings while others warn of the ETF's structural decay and remain locked in a heated debate over whether the semiconductor sector's parabolic trend is approaching a systemic correction or a continued bull run.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is gaining attention following a prime contract win with Belgian Defence to build the country's first national security satellite, coupled with a new board appointment intended to bolster its national security strategy. While the community remains frustrated by persistent selling pressure from private equity shareholders and a recurring failure to hold price support above double digits, investors are actively debating the stock's long-term potential as it shifts focus toward scalable space infrastructure and defense-led contracts.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is seeing heavy volatility as investors weigh strong quarterly performance against a pivot to user-first growth that signals a slowdown in near-term revenue. While some in the community see the $400 million buyback and solid fundamentals as a compelling buying opportunity, others are aggressively betting against the stock, citing intensifying competition from free AI tools and a perceived lack of a long-term moat.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The FDA indicated openness to alternative trial designs such as not using a placebo group for the Phase 3 trial.</li><li>Quoin remains on track to complete patient enrollment for the next phase, it added.</li><li>Last week, the FDA granted Fast Track designation to the company’s QRX003.</li></ul>Shares of Quoin Pharmaceuticals (QNRX) gave up most of its early gains to trade 1 % higher on Wednesday, after the company said it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) for its lead drug QRX003 to treat Netherton Syndrome, a genetic disorder that results in severe allergies.The FDA indicated that a single Phase 3 trial may be sufficient to support U.S. approval, rather than the usual two studies. The agency also showed openness to alternative trial designs like randomized withdrawal or delayed-start studies, instead of a traditional placebo-controlled Phase 3 trial.<h2 class="st-heading-2">Phase 3 Trial Remains On Track</h2>Following the Type C meeting, Quoin plans to move ahead with its Phase 3 program and remains on track to complete patient enrollment. The company said it could file for approval as early as 2027.“With our established network of U.S. and EU clinical trial sites, we are confident that we will be in a position to initiate our pivotal Phase 3 program and fully complete recruitment this year,” said CEO Michael Myers.This comes just a week after the FDA granted Fast Track designation to QRX003. The drug is currently being tested in two late-stage trials to evaluate safety and effectiveness. QRX003 has already received Orphan Drug status in both the U.S. and Europe.Quoin also&nbsp;submitted an Orphan Drug Designation (ODD) application for&nbsp;QRX003 in Japan and a&nbsp;Breakthrough Medicine Designation with the Saudi Food and Drug Authority earlier this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/QNRX">QNRX</a> flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said given the company’s potential, the stock has been “beaten down”<stembedurl>https://stocktwits.com/revuelto/message/648496398</stembedurl>The stock has been under heavy selling pressure this year, slumping around 45%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Quoin Pharmaceuticals Garners Buzz After FDA’s Comments On Netherton Syndrome Lead Drug

The U.S. Food and Drug Administration indicated that a single Phase 3 trial of QRX003 could be enough to support approval in the U.S.

Equity

Quoin Pharmaceuticals Gains FDA Alignment, Eyes Streamlined Path to First Netherton Syndrome Treatment

Quoin Pharmaceuticals (NASDAQ:QNRX) reported a key regulatory milestone following a constructive Type C meeting with the U.S. Food and Drug Administration (FDA), potentially accelerating the development path for its lead candidate, QRX003, in the treatment of Netherton Syndrome, a rare and underserved genetic skin disorder.

<ul class="summary-bullets"><li>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter.</li><li>The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others.</li><li>The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;</li></ul>&nbsp;Shares of Quoin Pharmaceuticals (QNRX) jumped as much as 39% on Tuesday after the company announced that the target loading concentrations for its two topical Rapamycin delivery technologies have been successfully achieved.A Rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/11/3185408/0/en/Quoin-Pharmaceuticals-Announces-Achievement-of-Topical-Rapamycin-Target-Loadings-for-Two-Proprietary-Delivery-Technologies.html">said</a>.<h2 class="st-heading-2">Path Forward</h2>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter. The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others. Microcystic lymphatic malformations are benign vascular anomalies characterized by a collection of small, abnormal lymphatic vessels and cysts, often appearing as small, skin-colored to pinkish or even dark, blister-like vesicles on the skin.Venous malformations, meanwhile, are present at birth, but not always visible, and are the most common type of vascular malformation. They are caused by veins that have not developed normally, resulting in tangled, enlarged vessels. Symptoms can include bluish or purplish spots, swelling, and pain.Neither microcystic lymphatic malformations nor venous malformations have FDA-approved treatments.<h2 class="st-heading-2">Executive Take Away</h2>According to Quoin CEO Michael Myers, initiating clinical development in microcystic lymphatic malformations and venous malformations will be complementary to the company’s pipeline.The firm is now looking forward to the commencement of pivotal studies for QRX003 in Netherton Syndrome by the end of the year, with the help of the financing of up to $105.3 million closed in October. Quoin’s overall pipeline comprises four products in development for Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, and Scleroderma, among others.<blockquote>“We believe that rapamycin loading concentrations of 4% and 5% in these proprietary delivery systems could potentially provide competitive advantages over other topical rapamycin formulations currently in development with similar drug loadings due to the ability of our technologies to optimize delivery of the drug at the target sites.” &nbsp; - Michael Myers, CEO, Quoin.</blockquote><h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QNRX">QNRX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.QNRX stock is down by 59% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/chamath-palihapitiya-talks-about-us-achilles-heel-when-it-comes-to-rare-earths/cLPdHr9REPH">Chamath Palihapitiya Talks About US' Achilles Heel When It Comes To Rare Earths</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? 

A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

Quoin Pharmaceuticals (QNRX) became the top-four trending ticker on Stocktwits on Friday morning after the stock jumped nearly 300% after the company announced that it has entered into a securities purchase agreement with new healthcare-focused institutional investors, with the potential to raise $104.5 million in gross proceeds.The late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases said that this purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.The firm added that&nbsp;the private placement was priced at a premium to the company’s prior day’s closing stock price. Quoin said that the financing includes participation from new healthcare-focused investors, including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others.Retail sentiment on <a href="https://stocktwits.com/symbol/QNRX">Quoin</a> jumped to ‘extremely bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.Quoin said it will issue an aggregate of 1,993,940 American Depository Shares (ADSs) and accompanying warrants to purchase up to an aggregate of 7,975,760 ADSs, at a combined purchase price of $8.25 per ADS and accompanying warrants.The company said it intends to use the upfront net proceeds for general corporate purposes, which may include operating expenses, research and development, including completion of clinical development of QRX003 for Netherton Syndrome, working capital, future acquisitions, and general capital expenditures.&nbsp;The aggregate net proceeds are expected to be sufficient to fund the company into 2027. Shares of Quoin have gained nearly 41% this year and have jumped 76% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kalshi-doubles-valuation-to-5-b-in-latest-funding-round-report/ch6aClnR3SM">Kalshi Doubles Valuation To $5B In Latest Funding Round: Report</a>

QNRX Stock Soars 300% After $104.5M Financing Through Private Placement

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Shares of Quoin Pharmaceuticals saw increased retail chatter on Wednesday after the company announced positive initial clinical data from its ongoing investigational new drug Pediatric Peeling Skin Syndrome (PSS) study evaluating QRX003.Twelve weeks of treatment produced a clear improvement in the patient's skin condition compared to initial baseline measurements.&nbsp;The stock closed at $7.65 on Wednesday, rising 20.3% during the day, but slipped 8% to $7.04 in after-hours trading.Clinical endpoints such as The Investigator's Global Assessment (IGA), Modified Ichthyosis Area Severity Index (M-IASI), and Children's Dermatology Life Quality Index (CDLQI) showed positive changes.&nbsp;The patient's IGA score changed from severe to mild, M-IASI decreased from 36 to 12, and CDLQI, the quality of life measure, fell from 19 to 11. The study reported no adverse events while administering QRX003 to patients.Quoin will extend the patient's treatment while performing additional clinical evaluations after 24 weeks of therapy.&nbsp;The firm continues to progress QRX003 through late-stage clinical trials targeting Netherton Syndrome, another uncommon skin condition.Peeling Skin Syndrome is a rare genetic disorder that manifests through excessive outer skin shedding, leading to persistent pain and itching.&nbsp;Without any existing approved treatments, the promising results from QRX003 trials suggest its potential importance if future studies confirm the positive outcomes.CEO Michael Myers stressed the clinical importance of observed improvements and pointed out QRX003's potential to become the first approved therapy for PSS, noting plans to expand the study internationally.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,314% surge in 24-hour message volume.One user noted that some investors with less conviction tend to sell just before market close, expressing hope that the stock would open at $20.&nbsp;<stembedurl>https://stocktwits.com/89gt/message/614698425</stembedurl>Another user highlighted the stock’s potential for rapid movement due to its very low float and recent positive news.<stembedurl>https://stocktwits.com/MasterofThePennies/message/614637863</stembedurl>The stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data

The stock closed up 20% on Wednesday, driven by promising patient outcomes and no reported adverse events for its Pediatric Peeling Skin Syndrome (PSS) drug, with further treatment and evaluations planned.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

QNRX
Quoin Pharmaceuticals Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest QNRX News

QNRXQuoin Pharmaceuticals Ltd - ADR